• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Organovo Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    3/27/25 8:05:09 AM ET
    $ONVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ONVO alert in real time by email
    8-K
    false000149725300014972532025-03-272025-03-27

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 27, 2025

     

     

    Organovo Holdings, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-35996

    27-1488943

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    11555 Sorrento Valley Rd

    Suite 100

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 224-1000

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    ONVO

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 7.01 Regulation FD Disclosure.

    On March 27, 2025, Organovo Holdings, Inc. issued a press release providing a business update. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 7.01, including the press release attached hereto as Exhibit 99.1, is being furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “1934 Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

     

     

    Number

    Description

     

     

    99.1

    Press Release dated March 27, 2025.

    104

    Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    ORGANOVO HOLDINGS, INC.

     

     

     

     

    Date:

    March 27, 2025

    By:

      /s/ Keith Murphy

     

     

     

    Name: Keith Murphy
    Title: Executive Chairman

     


    Get the next $ONVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ONVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ONVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Staskey Norm

      3 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      1/8/25 4:05:03 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Gobel David was granted 19,607 shares, increasing direct ownership by 100% to 39,214 units (SEC Form 4)

      4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      8/9/24 4:01:07 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Milhous Alison Tjosvold was granted 19,607 shares, increasing direct ownership by 50% to 58,821 units (SEC Form 4)

      4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)

      8/9/24 4:01:05 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of the FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA's push to phase out animal models, announced on April 10, is expected to provide a powerful accelerant to VivoSim's market adoption, disrupting a >$10B animal testing market with models that are more predictive and ethically sound. As FDA Commiss

      4/24/25 8:05:11 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • VivoSim to Carry Forward Organovo 3D Bioprinting

      SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (the "Company") announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc. A name change of the Company to VivoSim Labs, Inc. will be effective on April 24, 2025, and the Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "VIVS" at market open on April 24, 2025. No action is required by existing stockholders with respect to the name and ticker symbol change. The Company's common stock will continue to be listed on the Nasdaq Capital Market and the CUSIP number assigned to the Company's common stock (68620A302) wil

      4/23/25 8:05:21 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

      SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025. The Company expects to release full fiscal second-quarter financial results the week of June 9-13, 2025. The Company also gave guidance that, as its common stock has been trading above the $1.00 minimum bid price required, it expects to meet the requirements for continued listing on the Nasdaq Capita

      4/2/25 8:05:00 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    SEC Filings

    See more
    • Organovo Holdings Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - VivoSim Labs, INC. (0001497253) (Filer)

      4/24/25 8:30:13 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Organovo Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)

      4/23/25 8:06:08 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Organovo Holdings Inc.

      424B5 - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)

      4/11/25 9:16:35 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Organovo Holdings Inc.

      SC 13G - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      11/14/24 3:34:49 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

      SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      2/12/24 6:17:19 PM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Organovo Holdings Inc. (Amendment)

      SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)

      2/5/24 6:08:57 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ONVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

      BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu

      3/11/25 7:00:00 AM ET
      $GRCE
      $MTNB
      $ONVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Organovo Announces Appointment of Norman Staskey as Chief Financial Officer

      SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer. Mr. Staskey has worked for Danforth Advisors since 2021, working as Chief Financial Officer for clients such as Azitra, Inc., a biotechnology company developing novel dermatology therapeutic technologies. Norm has over 25 years working in capital market and M&A transactions most recently as a Managing Director in EY's (formally Ernst & Young) national transactions practice wh

      1/6/25 8:05:55 AM ET
      $ONVO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care